Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Morse

Showing results (1-10 of 124) with videos related to

Pageof 13
Sort By:
Current Opinion in Molecular Therapeutics|March 16, 2001
Technology evaluation: BLP-25, Biomira IncM A Morse
Current Opinion in Molecular Therapeutics|January 24, 2002
Technology evaluation: ISIS-2503, Isis PharmaceuticalsM A Morse
Idrugs : the Investigational Drugs Journal|June 24, 2005
American Society of Clinical Oncology - 37th Annual Meeting. Small molecule tyrosine kinase inhibitors. 12-15 May 2001, San Francisco, CA, USAM A Morse
Idrugs : the Investigational Drugs Journal|August 17, 2005
Stem cell therapy (Aastrom Biosciences Inc)M A Morse
Current Opinion in Molecular Therapeutics|March 16, 2001
Technology evaluation: Theratope, Biomira IncM A Morse
Current Opinion in Molecular Therapeutics|July 25, 2009
Technology evaluation: Stem-cell therapy, Aastrom Biosciences IncM A Morse
Gastroenterology|October 19, 2001
The role of glutathione S-transferase P1-1 in colorectal cancer: friend or foe?M A Morse
Current Opinion in Molecular Therapeutics|March 16, 2001
Technology evaluation: gene therapy (IL-2), Valentis IncM A Morse
Idrugs : the Investigational Drugs Journal|June 24, 2005
American Society of Clinical Oncology - 37th Annual Meeting. Novel antitumor agents. 12-15 May 2001, San Francisco, CA, USAM A Morse
Experimental Lung Research|July 11, 1998
Inhibition of NNK-induced lung tumorigenesis by modulators of NNK activationM A Morse
Pageof 13

Showing results (1-10 of 124) with videos related to

Sort By:
Pageof 13
Current Opinion in Molecular Therapeutics|March 16, 2001
Technology evaluation: BLP-25, Biomira IncM A Morse
Current Opinion in Molecular Therapeutics|January 24, 2002
Technology evaluation: ISIS-2503, Isis PharmaceuticalsM A Morse
Idrugs : the Investigational Drugs Journal|June 24, 2005
American Society of Clinical Oncology - 37th Annual Meeting. Small molecule tyrosine kinase inhibitors. 12-15 May 2001, San Francisco, CA, USAM A Morse
Idrugs : the Investigational Drugs Journal|August 17, 2005
Stem cell therapy (Aastrom Biosciences Inc)M A Morse
Current Opinion in Molecular Therapeutics|March 16, 2001
Technology evaluation: Theratope, Biomira IncM A Morse
Current Opinion in Molecular Therapeutics|July 25, 2009
Technology evaluation: Stem-cell therapy, Aastrom Biosciences IncM A Morse
Gastroenterology|October 19, 2001
The role of glutathione S-transferase P1-1 in colorectal cancer: friend or foe?M A Morse
Current Opinion in Molecular Therapeutics|March 16, 2001
Technology evaluation: gene therapy (IL-2), Valentis IncM A Morse
Idrugs : the Investigational Drugs Journal|June 24, 2005
American Society of Clinical Oncology - 37th Annual Meeting. Novel antitumor agents. 12-15 May 2001, San Francisco, CA, USAM A Morse
Experimental Lung Research|July 11, 1998
Inhibition of NNK-induced lung tumorigenesis by modulators of NNK activationM A Morse
Pageof 13